Trial Profile
Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Benzylguanine (Primary) ; Carmustine (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 10 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 02 Mar 2010 Actual number of patients (21) added as reported by ClinicalTrials.gov record.
- 02 Mar 2010 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov record.